| Edenbridge Pharmaceuticals, LLC |
42799070915 |
100mg Capsule, 15ct in 1 box |
Generic |
FDA |
2023-11-01 |
4018.5300 |
None |
1 |
12 |
None |
None |
None |
None |
None |
None |
None |
None |
| Edenbridge Pharmaceuticals, LLC |
82111095502 |
Hemady - 20mg Tablet, 100ct bottle |
Brand |
FDA |
2023-12-01 |
2739.7100 |
None |
1 |
10000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Edenbridge Pharmaceuticals, LLC |
42799095402 |
Donepezil HCl Oral Tablet 23 MG, 90ct 1 bottle |
Generic |
FDA |
2023-12-05 |
851.7700 |
None |
1 |
2000 |
None |
None |
None |
None |
None |
None |
This product has been listed in the compendium with an effective start date of 10/24/2023. The first lot of product is still in production, and the actual date of physical availability on the market is estimated to be in early December. |
None |
| Eisai Inc. |
62856021201 |
Leqembi 200mg/2ml |
Brand |
FDA |
2023-01-18 |
254.8100 |
Marketing Plan - During accelerated approval, Eisai's marketing engagements with healthcare professionals generally will be limited to and focused on understanding how an AD therapy will be integrated into practice.
Pricing Plan - Eisai considered a holistic approach in assessing value and making decisions that may affect patient access, so that our LEQEMBI pricing approach can maximize value for all stakeholders (patients, families, caregivers, healthcare providers, payers, employees and shareholders). This approach includes clinical outcome assessments of our medicines and the benefits we deliver to patients, their families and caregivers as the "clinical value," as well as the projected "social value" that help improve patients' and caregivers' quality of life and productivity. Moreover, we assess the simulated impact of our medicines on reducing demand for health services and global burden of disease as potential "economic value" while enhancing further innovations in AD.?
?Eisai decided to price LEQEMBI below the quantified societal value. For further details, including Eisai’s calculation of the societal value, please see Eisai’s press release dated January 6, 2023 titled EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE" |
None |
100000 |
1 |
1 |
None |
None |
None |
None |
Estimated Volume of Patients - "In the U.S., we estimate that the diagnosed eligible Early AD population will reach approximately 100,000 individuals by year 3 representing a measured initial attainment in the real world and will increase gradually over the mid-to-long term given the time required to advance new screening and diagnostic technologies such as blood-based biomarkers to confirm amyloid beta pathology." |
None |
| Eisai Inc. |
62856021501 |
Leqembi 500mg/5ml |
Brand |
FDA |
2023-01-18 |
637.0200 |
Marketing Plan - During accelerated approval, Eisai's marketing engagements with healthcare professionals generally will be limited to and focused on understanding how an AD therapy will be integrated into practice.
Pricing Plan - Eisai considered a holistic approach in assessing value and making decisions that may affect patient access, so that our LEQEMBI pricing approach can maximize value for all stakeholders (patients, families, caregivers, healthcare providers, payers, employees and shareholders). This approach includes clinical outcome assessments of our medicines and the benefits we deliver to patients, their families and caregivers as the "clinical value," as well as the projected "social value" that help improve patients' and caregivers' quality of life and productivity. Moreover, we assess the simulated impact of our medicines on reducing demand for health services and global burden of disease as potential "economic value" while enhancing further innovations in AD.?
?Eisai decided to price LEQEMBI below the quantified societal value. For further details, including Eisai’s calculation of the societal value, please see Eisai’s press release dated January 6, 2023 titled EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE" |
None |
100000 |
1 |
1 |
None |
None |
None |
None |
Estimated Volume of Patients - "In the U.S., we estimate that the diagnosed eligible Early AD population will reach approximately 100,000 individuals by year 3 representing a measured initial attainment in the real world and will increase gradually over the mid-to-long term given the time required to advance new screening and diagnostic technologies such as blood-based biomarkers to confirm amyloid beta pathology." |
None |
| Eli Lilly and Company |
00002702660 |
Jaypirca 100mg 60 tablets |
Brand |
FDA |
2023-01-27 |
21000.0000 |
None |
1 |
3500 |
None |
None |
2019-02-15 |
6920000000.0000 |
None |
Lilly acquired Loxo Oncology, Inc, on February 15, 2019 for a purchase price of approximately $6.92 billion, net of cash acquired. Under the terms of the agreement, Lilly acquired a pipeline of investigational medicines, including pirtobrutinib (Loxo-305). [https://investor.lilly.com/static-files/cd4a37af-ec28-449c-9bfb-ae380700209a] |
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells.
Based on data from the National Cancer Institutes’ SEER Cancer Statistics Review, approximately 3500 patients in the US are diagnosed with Mantle-cell lymphoma (MCL) per year. MCL incidence is 0.8 per 100,000 people. (SEER, 2017. Trends in SEER Incidence and US Mortality; 1975-2017. Table 19.26 All Lymphoid Neoplasms with Detailed Non-Hodgkin Lymphoma Subtypes 2008-2017. Available at: Non-Hodgkin Lymphoma, CSR 1975-2017 (cancer.gov)). People with MCL may or may not use Jaypirca.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jaypircatm-pirtobrutinib-first-and-only-non. |
None |
| Eli Lilly and Company |
00002690230 |
Jaypirca 50mg 30 tablets |
Brand |
FDA |
2023-01-27 |
7000.0000 |
None |
1 |
3500 |
None |
None |
2019-02-15 |
6920000000.0000 |
None |
Lilly acquired Loxo Oncology, Inc, on February 15, 2019 for a purchase price of approximately $6.92 billion, net of cash acquired. Under the terms of the agreement, Lilly acquired a pipeline of investigational medicines, including pirtobrutinib (Loxo-305). [https://investor.lilly.com/static-files/cd4a37af-ec28-449c-9bfb-ae380700209a] |
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells.
Based on data from the National Cancer Institutes’ SEER Cancer Statistics Review, approximately 3500 patients in the US are diagnosed with Mantle-cell lymphoma (MCL) per year. MCL incidence is 0.8 per 100,000 people. (SEER, 2017. Trends in SEER Incidence and US Mortality; 1975-2017. Table 19.26 All Lymphoid Neoplasms with Detailed Non-Hodgkin Lymphoma Subtypes 2008-2017. Available at: Non-Hodgkin Lymphoma, CSR 1975-2017 (cancer.gov)). People with MCL may or may not use Jaypirca.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jaypircatm-pirtobrutinib-first-and-only-non. |
None |
| Eli Lilly and Company |
00002801127 |
OMVOH 100 mg/mL 2 single patient-use prefilled pens |
Brand |
FDA |
2023-10-27 |
10360.6700 |
None |
1 |
730000 |
None |
None |
None |
None |
None |
None |
Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL) is the first and only FDA approved interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Marking a significant milestone, Omvoh is the only UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to UC.
Approximately 730,000 adults in the United States have ulcerative colitis (see, for example Prevalence of Inflammatory Bowel Disease Among Medicare Fee-For-Service Beneficiaries — United States, 2001-2018 | MMWR at https://www.cdc.gov/mmwr/volumes/70/wr/mm7019a2.htm# (estimating prevalence in adults 65 and older) and Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007–2016 | Inflammatory Bowel Diseases | Oxford Academic at https://academic.oup.com/ibdjournal/article/26/4/619/5554163 (estimating prevalence in adults 18-65); see also Definition & Facts of Ulcerative Colitis - NIDDK at https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/definition-facts). People with ulcerative colitis may or may not use Omvoh.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class. |
None |
| Eli Lilly and Company |
00002757501 |
OMVOH 20 mg/mL (300 mg/15 mL) 1 300 mg vial |
Brand |
FDA |
2023-10-27 |
9593.2200 |
None |
1 |
730000 |
None |
None |
None |
None |
None |
None |
Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL) is the first and only FDA approved interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Marking a significant milestone, Omvoh is the only UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to UC.
Approximately 730,000 adults in the United States have ulcerative colitis (see, for example Prevalence of Inflammatory Bowel Disease Among Medicare Fee-For-Service Beneficiaries — United States, 2001-2018 | MMWR at https://www.cdc.gov/mmwr/volumes/70/wr/mm7019a2.htm# (estimating prevalence in adults 65 and older) and Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007–2016 | Inflammatory Bowel Diseases | Oxford Academic at https://academic.oup.com/ibdjournal/article/26/4/619/5554163 (estimating prevalence in adults 18-65); see also Definition & Facts of Ulcerative Colitis - NIDDK at https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/definition-facts). People with ulcerative colitis may or may not use Omvoh.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class. |
None |
| Eli Lilly and Company |
00002247180 |
ZepboundTM 10mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Eli Lilly and Company |
00002246080 |
ZepboundTM 12.5mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Eli Lilly and Company |
00002245780 |
ZepboundTM 15mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Eli Lilly and Company |
00002250680 |
ZepboundTM 2.5mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Eli Lilly and Company |
00002249580 |
ZepboundTM 5mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Eli Lilly and Company |
00002248480 |
ZepboundTM 7.5mg/ 0.5 mL 4 single-dose pens |
Brand |
FDA |
2023-11-09 |
1059.8700 |
None |
1 |
124000000 |
None |
1 |
None |
None |
None |
None |
Zepbound™ (tirzepatide) injection is the first and only obesity treatment that works by activating both GIP and GLP-1 hormone receptors. Zepbound is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Zepbound was approved by the FDA in November 2023.
Zepbound™ (tirzepatide) is indicated for use in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese); or a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Based on an abstract submitted to the Journal of the American College of Cardiology, data from the National Health and Nutrition Examination Survey (NHANES) from 2015-2018 showed 51% (124 million) of US adults were eligible for anti-obesity medications. (Journal of American College of Cardiology, Volume 79, Issue 9, Supplement, 2022, page 1444. Available at: https://doi.org/10.1016/S0735-1097(22)02435-4). Eligible patients may or may not use Zepbound.
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. |
None |
| Epic Pharma |
42806037230 |
Deferasirox 180mg Oral Granules 30 sachets |
Generic |
FDA |
2023-04-12 |
2049.9800 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Epic Pharma |
42806037330 |
Deferasirox 360mg Oral Granules 30 sachets |
Generic |
FDA |
2023-04-12 |
4099.8700 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Epic Pharma |
42806037130 |
Deferasirox 90mg Oral Granules 30 sachets |
Generic |
FDA |
2023-04-12 |
1025.0100 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Exelan Pharmaceuticals, Inc. |
76282071527 |
Pirfenidone Capsules 267mg 270ct |
Generic |
FDA |
2023-01-23 |
5194.5600 |
None |
1 |
100000 |
None |
None |
None |
None |
None |
None |
None |
None |
| Exelan Pharmaceuticals, Inc. |
76282052530 |
Lurasidone HCL 120mg Tab 30ct |
Generic |
FDA |
2023-09-29 |
1221.4600 |
None |
1 |
2400000 |
None |
None |
None |
None |
None |
None |
Product was not acquired |
None |